Alemtuzumab, cladribine, fingolimod, and natalizumab as first-line treatments in adult patients with highly active relapsing multiple sclerosis

CDA-AMC
Record ID 32018016021
English
Authors' objectives: Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system, in which the immune system causes an inflammatory response that damages or destroys myelin, axons, and oligodendrocytes. Damaged myelin forms scar tissue (sclerosis) that replaces the myelin and, as a result, nerve impulses transmitted to and from the brain and spinal cord are distorted or interrupted, producing a variety of symptoms. Fingolimod, cladribine, natalizumab, and alemtuzumab have been approved by Health Canada for the treatment of MS. These drugs are generally reserved for patients with poor response or tolerability with first-line drugs. This review will evaluate the clinical efficacy and safety of alemtuzumab, natalizumab, cladribine, and fingolimod as first-line treatments in patients with highly active relapsing MS.
Details
Project Status: Completed
URL for project: https://www.cda-amc.ca/alemtuzumab-cladribine-fingolimod-and-natalizumab-first-line-treatments-adult-patients-highly
Year Published: 2024
URL for published report: https://www.cda-amc.ca/sites/default/files/hta-he/HT0038%20MS_Final%20Report_Internal.pdf
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Multiple Sclerosis
  • Multiple Sclerosis, Relapsing-Remitting
  • Alemtuzumab
  • Cladribine
  • Fingolimod Hydrochloride
  • Natalizumab
  • Rituximab
  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • Adult
Contact
Organisation Name: Canada’s Drug Agency (CDA-AMC)
Contact Address: 865 Carling Ave., Suite 600 Ottawa, ON Canada K1S 5S8
Contact Name: Shannon Nordstrom
Contact Email: shannon.nordstrom@cda-amc.ca
Copyright: 2025 Canadian Agency for Drugs and Technologies in Health
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.